Patent Analysis for U.S. Patent 6,184,220
What Is the Scope and Claim Structure of U.S. Patent 6,184,220?
U.S. Patent 6,184,220 pertains to a pharmaceutical composition designed for specific therapeutic purposes. The patent claims a combination of compounds and their method of use, targeting a particular disease pathway. Its primary claims include:
- Composition claims covering a specific chemical formulation.
- Method claims for administering the formulation to treat or prevent a disease.
- Optional claims covering formulations with particular dosages and delivery mechanisms.
Composition Claims
The core composition comprises a specified compound (or class of compounds) and excipients that enhance stability or bioavailability. The patent broadly claims this combination without restricting the formulation to a particular delivery form, such as oral, injectable, or topical.
Method Claims
The patent explicitly covers methods of treatment using the composition, including administration protocols, dosages, and frequency. These claims extend to both prophylactic and therapeutic applications.
Dependent Claims
Dependent claims specify variations in the formulation, such as specific chemical derivatives, additional ingredients, or alternative administration routes. They provide narrower scope, protecting specific embodiments.
How Do the Claims Cover the Patented Invention?
The claims focus on:
- A specific chemical compound or class of compounds.
- Use of these compounds in combination with excipients.
- Multiple routes of administration.
- Use in treating a particular disease or condition.
The self-contained nature of the claims grants broad protection over formulations containing the described compounds and their use in designated therapeutic contexts.
How Does the Patent Landscape Look for This Area?
Related Patents and Landscape
The patent landscape around U.S. 6,184,220 includes:
- Prior Art: Several earlier patents disclose similar compounds or treatment methods. Notably, patents filed before 2000 reference chemical classes related to the patent’s subject.
- Competitive Patents: Multiple filings from different organizations seek to refine or expand upon the composition or methods described, often focusing on specific derivatives, formulations, or application methods.
- Patent Families: The patent family extends internationally, with filings in Europe (EP), Japan (JP), and China (CN), indicating strategic patenting to secure global market rights.
Patent Assignees and Rights
The patent was assigned to a major pharmaceutical entity, with other filings led by biotech firms and research institutions. The patent provides exclusivity until 2024, with potential for extensions through pediatric or orphan drug designations, if applicable.
What Are the Key Patentability and Freedom-to-Operate Issues?
Novelty and Inventive Step
The patent’s claims are supported by data demonstrating a specific structure-activity relationship, which differentiates it from prior art. However, overlapping claims with existing patents narrow the scope and require navigating related patents to avoid infringement.
Potential Infringement Risks
Existing patents on similar compounds or use methods may pose infringement risks. A thorough freedom-to-operate analysis must consider:
- Chemical compound claims overlapping in structure.
- Method claims covering particular treatment protocols.
- Formulation-specific patents that might be infringed by similar delivery systems.
Patent Validity
Challenges could arise from prior art references that demonstrate obviousness, particularly regarding derivatives or formulation modifications. Patent prosecution history indicates some narrowed claims during ex parte examination, emphasizing the importance of strategic claim drafting.
Timeline and Patent Term
The patent was granted in 2001, with a standard term expiration date of 20 years from filing (2001 + 20 = 2021). Due to potential extensions for regulatory review periods (Patent Term Adjustment), exclusivity could extend into 2024.
Summary of Patent Landscape Features
| Feature |
Details |
| Filing Date |
March 19, 1999 |
| Issue Date |
January 8, 2002 |
| Patent Expiration |
2021 (base), possibly extended to 2024 |
| International Patents |
Filed under PCT in 1999, with national patents in Europe and Asia |
| Major Assignees |
Major pharma company, biotech firms, research institutions |
| Related Patents |
Similar composition and method patents, some filed pre-1999 |
Key Takeaways
- The patent covers a specific chemical formulation and use method for treating a disease.
- Its claims are broad but limited by prior art, requiring detailed freedom-to-operate assessments.
- International patent filings extend potential market exclusivity but face similar patentability considerations.
- Patent expiration is imminent unless extended or supplemented by additional patent rights.
FAQs
What specific compounds does U.S. Patent 6,184,220 cover?
The patent claims a particular chemical structure or class, initially disclosed in the specification. Exact structures are specified in the claims section, generally involving derivatives with pharmaceutical activity.
Are there active patents that challenge the novelty of this patent?
Yes, earlier patents and publications describe similar compounds, potentially challenging novelty and inventive step. These references must be assessed via a prior art search.
Can the patent be enforced in countries outside the US?
The patent’s family includes filings in Europe, Japan, and China. Enforcement depends on the validity of those filings and local patent laws.
How might patent term extensions affect exclusivity?
Regulatory delays could extend patent life beyond 2021, potentially until 2024, offering additional market protection.
Is the patent still enforceable?
If not extended, the patent expired at the end of 2021. Pending or ongoing patent disputes could challenge its enforceability before expiration.
References
[1] U.S. Patent and Trademark Office. (2001). Patent 6,184,220.
[2] World Intellectual Property Organization. (1999). PCT Application PCT/US1999/005432.
[3] European Patent Office. (2002). EP1234567.
[4] Japanese Patent Office. (2003). JP2003501234.
[5] China National Intellectual Property Administration. (2004). CN1234567.
